Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study

This study is a Phase II placebo-controlled, double-blind study, looking at the safety and efficacy of Lisdexamfetamine dimesylate (LDX) in people with MS with cognitive impairment.

LDX is an inactive amphetamine prodrug which is currently approved for attention deficit disorder. Patients included in the study had clinically definite MS and impaired on either of two primary outcomes: the Symbol Digit Modalities Test (SDMT) or the Paced Auditory Serial Addition Test (PASAT). Both are measures of cognitive processing speed.

Secondary outcomes were the Brief Visuospatial Memory Test Revised (BVMTR), the California Verbal Learning Test 2nd edition (CVLT2). Both of these are measures of episodic memory. Also included was a self-report measure of executive function using the Behavoiural Rating Invenory of Executive Function for Adults (BRIEF-A).

Results showed that there was significant improvement in the SDMT and CVLT2 score in the LDX group when compared to the placebo group. There was a high proportion of adverse events reported in both the LDX-treated and placebo-treated subjects. This study suggests an improvement in processing speed and memory in cognitively impaired MS patients.

Further studies are needed as this data is based on a small sample size and the treated and nontreated groups were not optimally balanced on all outcomes at baseline.

Authors:
Morrow SA, Smerbeck A, Patrick K

Source: J Neurol. 2012 Sep 23. [Epub ahead of print]

Read the abstract

 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial